宜華健康(000150.SZ)擬定增募資不超10.53億元 由中冠寶投資和華夏人壽認購
格隆匯3月17日丨宜華健康(000150.SZ)披露2020年度非公開發行A股股票預案,擬非公開發行股票的發行數量不超過發行前總股本的30%,即不超過約2.6331億股(含),發行對象為中冠寶投資和華夏人壽2名特定投資者。
發行價格不低於定價基準日前二十個交易日公司股票均價的80%,即3.54元/股,各方協商確定最終發行價為4元/股。
募集資金總額不超過約10.53億元,此次募集資金總額在扣除發行費用後7.5億元用於償還銀行貸款,其餘資金用於補充流動資金。
若實際募集資金數額(扣除發行費用後)少於上述金額,以實際募集資金數額按照上述金額對應比例計算金額為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.